Document is current
Any future updates will be listed below
-
Authors
Lorman-Carbó, Natàlia
Martínez-Sáez, Olga
Fernandez-Martinez, Aranzazu
Galván, Patricia
Chic, Nuria
Garcia-Fructuoso, Isabel
Rodríguez, Adela
Gómez-Bravo, Raquel
Schettini, Francesco
Blasco, Paula
Castillo, Oleguer
González-Farré, Blanca
Adamo, Barbara
Vidal, Maria
Muñoz, Montserrat
Perou, Charles M.
Malumbres, Marcos
Gavilá, Joaquín
Pascual, Tomás
Prat, Aleix
Brasó-Maristany, Fara
-
Funding
Funding for this research was provided by:
Fundación SEOM, Becas FSEOM para Formación en Investigación en Centros de Referencia en el Extranjero 2021
Fundació la Marató de TV3 (201935-30)
Fundación CRIS contra el cáncer (PR_EX_2021-14)
Agència de Gestó d'Ajuts Universitaris i de Recerca 2021 (SGR 01156)
Fundación Fero (BECA ONCOXXI21)
Instituto de Salud Carlos III (PI22/01017)
Asociación Cáncer de Mama Metastásico IV Premios M. Chiara Giorgetti
Breast Cancer Research Foundation (BCRF-22-198 and BCRF-23-198)
RESCUER, funded by European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement (No. 847912)
Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS)
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 8 July 2024
First Online: 11 July 2024
Competing interests
: A.P. reports advisory and consulting fees from Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardan Health, Peptomyc and Lilly, lecture fees from Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies and Daiichi Sankyo, institutional financial interests from Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia inno. Research, SL, Celgene, Astellas and Pfizer; stockholder and consultant of Reveal Genomics, SL; patents filed PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. F.B-M. has patents filed: PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369 and part-time employment with Reveal Genomics, SL. J.G. reports scientific advisory board fees from Novartis, Pfizer and Lilly, consultancy training fees from Roche, Novartis and MSD, honoraria fees from Roche, Novartis and Pfizer. I.G-F. reports financing of courses and talks from Novartis. The remaining authors declare no competing interests.
